Trial Profile

Phase II, Randomized, Double-blind, Placebo-controlled Study of Nitazoxanide in Combination With Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Patients With Hepatitis C.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Jan 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nitazoxanide (Primary) ; Peginterferon alfa-2a; Ribavirin
Indications Hepatitis C
Focus Therapeutic Use
Acronyms STEALTH C-3
Sponsors Romark Laboratories

Most Recent Events

30 May 2012 Actual end date Apr 2010 added as reported by ClinicalTrials.gov.
30 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
04 May 2010 Results presented orally at the Late-Breaking forum of the American Gastroenterological Association Institute during Digestive Disease Week (DDW), as reported by Romark Laboratories.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com